ESR1 and breast cancer: Clinically relevant, the absence of agonistic activity by compound 35 in endometrial cells might prevent pro-tumoral effects linked to partial agonism of current SERMs, besides potentiating the antiestrogenic effects of 4-OHTAM on ER+ BC cells.